Overview

Bioequivalence Study of Different Aprocitentan Tablet Formulations

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The main purpose is to study the pharmacokinetics of aprocitentan (ACT-132577) using 2 different tablet formulations. The clinical pharmacology data will be used to determine bioequivalence of 2 different tablet formulations.
Phase:
Phase 1
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.